Search results
Results from the WOW.Com Content Network
Download as PDF; Printable version; In other projects ... Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6 ...
Malignant melanoma of the extremities, multiple myeloma, conditioning treatment before haemopoietic stem cell transplant. Myelosuppression, pulmonary fibrosis and pneumonitis (uncommon), skin necrosis (uncommon), anaphylaxis, hepatic sinusoidal obstruction syndrome and SIADH. Secondary malignancies. [16] Streptozotocin: IV, PO: Alkylates DNA.
B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia Camrelizumab [22] mab: humanized: PD-1: hepatocellular carcinoma: Canakinumab [43] Ilaris: mab: human: IL-1: Y: cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease: Cantuzumab mertansine [42] mab: humanized ...
Non-Hodgkin’s lymphoma (NHL) is one of the most common forms of blood cancer.1 The American Cancer Society estimates that about 81,560 people in the U.S. will be diagnosed with NHL and about ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
In 1966, the organization was renamed Leukemia Society of America. In 1968, the Leukemia Society of America published Closing In, Research on Leukemia, a book summarizing its progress in fighting leukemia. [8] In 1968, the Patient Services Committee created the Patient Aid Programs that helped cover patient medications, lab fees, blood ...
In many cases, Imatinib can induce a complete cytogenetic response (CCyR) and major molecular response (MMR) and many patients can have a long-term remission. It is also used to maintain remission in chronic phase CML patients. While Imatinib is a very effective treatment for CML and some types of ALL, it is not a cure for leukemia.